Enteral Access Technologies Secures £500K to Expand DoubleCHEK Patient Safety Device Globally
In a significant boost for UK‑based medical device innovation, Enteral Access Technologies, Ltd. (EAT), the Liverpool‑headquartered developer of the DoubleCHEK patient safety device, has secured fresh funding aimed at accelerating the company’s international expansion and commercial rollout. Founded in 2018 and focused on improving the safety of nasogastric and orogastric tube placement, the company has been steadily building momentum in both clinical adoption and investor confidence.
The most recent financing round, announced in November 2025, saw Enteral Access Technologies raise £500,000 in a bridging funding round led by British Design Fund, a venture firm known for backing design‑led and purpose‑driven startups. This injection of capital is intended to help scale the commercialization of DoubleCHEK beyond the UK into markets such as the United States and broader Europe, where the company reports growing clinical interest and initial uptake.
DoubleCHEK is designed to enable safer bedside confirmation of feeding tube placement by combining carbon dioxide (CO₂) detection with pH measurement in a single, easy‑to‑interpret device. This dual‑indicator approach aims to reduce reliance on X‑rays and conventional methods that can be slower, more subjective, or expose patients to unnecessary radiation — factors that contribute significantly to misplacement incidents in clinical settings. EAT’s technology aligns with evolving safety guidance and has seen early adoption in NHS facilities and other healthcare systems, with repeat orders indicating promising clinical traction.
In addition to the recent British Design Fund‑led round, EAT’s funding history includes backing from a diverse group of investors active in healthtech and early‑stage innovation. Prior financing rounds have included support from Puffin Point, a London‑based family office that provided crucial early capital and strategic support as the company worked to bring DoubleCHEK to market. Puffin Point’s involvement included not only financial investment but also network access and advisory expertise, exemplifying the hybrid role that family offices can play in scaling niche medtech companies.
Other investors identified in industry funding databases include Freyr Investments, Namier Capital Partners, and WilkinsonFuture, underscoring a varied investor base that spans venture capital, private equity, and specialist seed backers. These stakeholders have collectively contributed to Enteral Access Technologies’ total funding to date, which data platforms report at approximately $4.59 million raised across multiple rounds.
Industry observers view this capital backing as reflective of broader momentum in the enteral feeding devices market, which analysts project to sustain robust growth over the coming decade. Market research firms estimate that the global enteral feeding devices sector could reach valuations approaching $4 billion by 2030, with compounded annual growth rates in the high single digits fueled by demographic trends, chronic disease prevalence, and technological advancements in patient safety and home care delivery. These market dynamics provide a favorable backdrop for companies like EAT seeking to differentiate with clinically validated, cost‑effective solutions.
Commenting on the 2025 funding announcement, Enteral Access Technologies’ CEO George Gallagher emphasized that the investment signifies strong support for the company’s mission to improve patient safety worldwide and validates market interest in the DoubleCHEK approach. The company has indicated that the new capital will be deployed to advance development efforts while accelerating the international rollout of its technology to healthcare providers, ensuring that the device reaches clinicians in diverse care settings.
As Enteral Access Technologies enters this next phase of growth, its blend of strategic investor support and clinical traction underscores the persistent demand for innovations that tackle long‑standing safety challenges in enteral access — a critical component of care for millions of patients with complex nutritional needs. The company’s progress also highlights the active role that UK healthtech startups and their investors are playing in global medtech markets, particularly in areas where practical, evidence‑driven tools can deliver immediate improvements in clinical practice.
